Clomiphene

Clomiphene is chosen when a stronger LH/FSH push is warranted, typically after a long, heavily suppressive cycle where tamoxifen alone may not produce sufficient recovery speed. It is also used when prior PCT attempts with tamoxifen alone produced incomplete recovery.

Some users prefer the combination of low-dose clomiphene and tamoxifen for the synergistic HPTA stimulation, using 25mg clomiphene alongside 20mg tamoxifen rather than high doses of either.

Use case: PCT tool for stimulating LH and FSH output. Some users respond well, others feel noticeably worse on it.

Administration: Usually once daily. Higher doses are not automatically better.

Decision rule: If recovery markers improve but the patient feels awful, switch strategy rather than forcing longer exposure.

Stop or reduce if: visual disturbances or significant mood instability appear.

Clomiphene citrate is a SERM with a different receptor binding profile than Tamoxifen. It stimulates LH and FSH release more potently than tamoxifen at comparable doses, making it the stronger choice for users who need a harder HPTA restart. However, its tolerability profile is meaningfully worse: mood instability, emotional lability, anxiety, and visual disturbances (light sensitivity, halos, afterimages) occur in a significant minority of users.

The visual disturbances are worth taking seriously. While typically reversible, persistent visual changes on clomiphene require stopping the compound. Continuing through visual symptoms is not recommended.

Clomiphene exists as two isomers: enclomiphene (the active isomer for LH/FSH stimulation) and zuclomiphene (which is estrogenic and responsible for many of the mood effects). Pharmaceutical-grade clomiphene contains both. Enclomiphene as an isolated compound is sometimes available and has a better tolerability profile, though it is less commonly accessible.

Staying on clomiphene through significant mood or visual side effects. The compound’s LH effect can be replicated at lower doses or replaced with tamoxifen, there is no reason to continue if it is clearly not tolerated.

Using clomiphene as a standard PCT protocol regardless of cycle duration or suppression level. For mild suppression (short cycle, moderate compounds), tamoxifen alone is usually sufficient. Clomiphene is more appropriate for harder recovery situations.

Assuming longer is better for recovery speed. PCT length is driven by lab confirmation of recovery, not by compound duration.

Compared with Tamoxifen, clomiphene produces stronger LH stimulation but significantly worse tolerability in mood-sensitive users. Tamoxifen is the first-line PCT choice for most users. Clomiphene is the escalation tool when tamoxifen is insufficient or when cycle suppression is severe enough to warrant a stronger push from the start.